Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease

FDAhigh relevance

Patient population match (advanced)

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

ClinicalTrials.govhigh relevance

Entity match (national cancer institute); Patient population match (advanced)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

ClinicalTrials.govhigh relevance

Entity match (national cancer institute); Patient population match (advanced)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

ClinicalTrials.govhigh relevance

Entity match (national cancer institute); Patient population match (advanced)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

ClinicalTrials.govhigh relevance

Entity match (national cancer institute); Patient population match (advanced)

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

ClinicalTrials.govhigh relevance

Entity match (national cancer institute)

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o

ClinicalTrials.govhigh relevance

Entity match (national cancer institute)

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

ClinicalTrials.govhigh relevance

Entity match (national cancer institute)

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Merckhigh relevance

Sponsor/company relevance (Merck); Patient population match (advanced)

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

Bristol Myers Squibbhigh relevance

Sponsor/company relevance (Bristol Myers Squibb); Patient population match (advanced)

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

Humanexa Signalsmedium relevance

Patient population match (advanced)

Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients

Humanexa Signalsmedium relevance

Moderate corpus alignment

Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise

Humanexa Signalsmedium relevance

Moderate corpus alignment

Study on Frailty in Young Adult Survivors of Childhood Cancer Highlights Long-term Health Risks

Humanexa Signalsmedium relevance

Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.

PubMedmedium relevance

Moderate corpus alignment

Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.

PubMedmedium relevance

Moderate corpus alignment

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.

PubMedmedium relevance

Moderate corpus alignment

Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.

PubMedmedium relevance

Moderate corpus alignment

Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors.

PubMedmedium relevance

Moderate corpus alignment